In Conversation

What sets Denmark apart is not just its policy direction but the openness of its regulatory culture. There’s a genuine willingness among stakeholders to engage in…

Our goal is to develop genome editing therapies that are both highly potent and fundamentally safe.

 Denmark is not only a place to observe innovation. It’s a place where you can work with both public and private sectors – so come and…

We launched the world’s first dedicated neurodegeneration investment fund at a time when the field was seen as a graveyard for drug development. But I believed…

We believe the future is bright...Cannabis is growing at over 20 percent annually, and we are ready to grow with it.

In biotech, resilience is essential, and the ability to halt a programme early if it is not working is just as important as pushing forward when…

It is critical that Europe, and Switzerland in particular, continues to play a leadership role—not just in science, but in technology and AI-driven drug discovery as…

The sheer diversity and complexity of ATMPs necessitate that assessors maintain cutting-edge knowledge supported not only through training programmes, but also interdisciplinary collaboration across clinical, quality,…

Caring about our health prevents us from many diseases and supports a long and happy life.   

Denmark must remain a country that values innovation, with a system ready to adopt the most effective, safest, and most patient-centred treatments available.

What began as a focused effort has become a multifaceted operation grounded in strong values and a collaborative spirit.

Success is deeply rooted in principles. At Principia, we don’t just deliver expertise—we lead with empathy, clarity, and commitment. That’s how we build trust, and that’s…

We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here